Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
BACKGROUND
The ongoing search for more effective agents in the treatment of uterine leiomyosarcomas is warranted because of the poor prognosis related to these tumors.


METHODS
A case of advanced, recurrent and refractory uterine leiomyosarcoma is presented that responded to trabectedin (ET-743) 1.2 mg/m2 intravenously over 24 h every 3 weeks after failing four prior regimens. A durable objective response lasting at least 8 months was documented.


CONCLUSIONS
Trabectedin (ET-743) has activity in uterine leiomyosarcoma and warrants further investigation.
Tewari
Devansu
D
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA.
Saffari
Bahman
B
Cowan
Carol
C
Wallick
Anita C
AC
Koontz
M Zach
MZ
Monk
Bradley J
BJ
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D004149:Dioxoles / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D015507:Drugs, Investigational / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000556:secondary; D009364:Neoplasm Recurrence, Local; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D000077606:Trabectedin; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D015507:Drugs, Investigational; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin